Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.

This guidance has been re-issued after a change to the commercial arrangements in August 2016. This change does not affect cost effectiveness. The following sections of the guidance have been updated: recommendation 1.1; sections 2.33.20, 3.34, 3.36, 4.19, 4.21, 4.32 and 5.4; and the table summarising the appraisal committee’s key conclusions.

This guidance replaces NICE technology appraisal guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA255). It does not cover the use of cabazitaxel for people who have had docetaxel and then abiraterone, enzalutamide or radium‑223 dichloride because the committee was not presented with evidence about the clinical and cost effectiveness of cabazitaxel for this population.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: May 2019





Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)